Quest Diagnostics (DGX) SVP logs option, RSU grants and tax share disposals

Rhea-AI Filing Summary

Quest Diagnostics SVP and Chief Accounting Officer Michael J. Deppe reported a mix of equity grants and related tax share withholdings. On February 18, 2026, he was granted a non‑qualified stock option covering 1,688 shares, which vests in three equal annual installments beginning on the first anniversary of the grant date.

He also received an award of 366 restricted stock units. To cover tax withholding from vesting RSUs, 83 shares of common stock at $210.01 and 99 shares at $206.99 were disposed of to the issuer. After these transactions, he directly owns 34,560 shares of common stock and holds 1,688 options, plus an additional 706 shares indirectly through the company’s 401(k) plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Deppe Michael J

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Corp. Controller & CAO

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/18/2026		A		366	A	$0	34,742	D
Common Stock	02/18/2026		F		83(2)	D	$210.01	34,659	D
Common Stock	02/18/2026		F		99(2)	D	$206.99	34,560(3)	D
Common Stock								706(4)	I	401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualifed Stock Option (right to buy)	$204.96	02/18/2026		A		1,688		(5)	02/18/2036	Common Stock	1,688	$0	1,688	D

Explanation of Responses:

1. Represents an award of restricted stock units.

2. Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units.

3. The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.

4. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

5. The options vest in three equal annual installments beginning on the first annual anniversary of the grant date.

Remarks:

	Sean D. Mersten, Attorney in Fact for Michael J. Deppe	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Quest Diagnostics (DGX) report for Michael J. Deppe?

Michael J. Deppe reported receiving 1,688 non-qualified stock options and 366 restricted stock units, plus tax-related dispositions of 83 and 99 common shares. These transactions reflect equity compensation grants and associated share withholdings for tax obligations on vested restricted stock units.

How many Quest Diagnostics (DGX) stock options were granted to Michael J. Deppe?

Michael J. Deppe was granted non-qualified stock options covering 1,688 shares of Quest Diagnostics common stock. These options vest in three equal annual installments, beginning on the first anniversary of the grant date, aligning his long-term compensation with company performance and shareholder value.

What restricted stock unit (RSU) awards did Michael J. Deppe receive from Quest Diagnostics (DGX)?

He received an award of 366 restricted stock units in Quest Diagnostics common stock. A related footnote clarifies this as an RSU grant, which typically converts into shares upon vesting, forming part of his equity-based compensation package as a senior executive officer.

Why were some Quest Diagnostics (DGX) shares disposed of in Michael J. Deppe’s Form 4?

The filing shows 83 shares at $210.01 and 99 shares at $206.99 were disposed of solely to cover tax withholding obligations from vested restricted stock units. These are tax-withholding dispositions to the issuer, not open-market sales to third-party buyers.

What is Michael J. Deppe’s Quest Diagnostics (DGX) share ownership after these transactions?

After the reported transactions, Michael J. Deppe directly owns 34,560 shares of Quest Diagnostics common stock and holds 1,688 stock options. He also has an indirect interest in 706 shares held through the company’s tax-qualified Profit Sharing (401(k)) Plan.

How are Michael J. Deppe’s 401(k) holdings in Quest Diagnostics (DGX) stock reported?

The Form 4 reports 706 shares of Quest Diagnostics common stock held indirectly through the company’s 401(k) plan. A footnote explains these shares are acquired periodically by the plan trustee, with share amounts based on account balances and prevailing market prices.